U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024732) titled 'A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration' on June 05.
Brief Summary: The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).
The main question it aims to answer is: Is PST-611-CT1 safe for participants?
Participants will:
* Receive a single dose of PST-611
* Will be followed up for a total of 16 weeks following PST-611 administration
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Dry Age Related Macular Degener...